Terms: = Bone cancer AND GPC3, OCI-5, 2719, ENSG00000147257, SGBS, SGB, DGSX, SDYS, P51654, AC002420_1, SGBS1 AND Treatment
3 results:
1. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with treatment-Naïve Acute Myeloid Leukemia.
Konopleva M; Thirman MJ; Pratz KW; Garcia JS; Recher C; Pullarkat V; Kantarjian HM; DiNardo CD; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Wei AH
Clin Cancer Res; 2022 Jul; 28(13):2744-2752. PubMed ID: 35063965
[TBL] [Abstract] [Full Text] [Related]
2. Targeting acute myeloid leukemia cells by CD33 receptor-specific MoS
Štefík P; Annušová A; Lakatoš B; Elefantová K; Čepcová L; Hofbauerová M; Kálosi A; Jergel M; Majková E; Šiffalovič P
Biomed Mater; 2021 Aug; 16(5):. PubMed ID: 34280914
[TBL] [Abstract] [Full Text] [Related]
3. bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population.
Jung JW; Yoon SM; Kim S; Jeon YH; Yoon BH; Yang SG; Kim MK; Choe S; Kuo MM
Oncotarget; 2016 Nov; 7(45):73754-73768. PubMed ID: 27650540
[TBL] [Abstract] [Full Text] [Related]
